Inhibition of morphine metabolism by ketamine

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 728-731

  Qi, Xiaoxin ^a   Evans, Allan M ^a   Wang, Jiping ^a   Miners, John O ^b   Upton, Richard N ^c   Milne, Robert W ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MORPHINE; MORPHINE 3 GLUCURONIDE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSFORMATION; GLUCURONIDATION; IN VITRO STUDY; LIVER MICROSOME; LIVER PERFUSION; MICHAELIS MENTEN KINETICS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ANIMALS; BILE; BIOCATALYSIS; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; KETAMINE; KINETICS; LIVER; MALE; METABOLISM; MICROSOMES, LIVER; MORPHINE; MORPHINE DERIVATIVES; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 77950934804     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030957     Document Type: Article

References (25)

1. Bell RF (1999) Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 83:101-103. (Pubitemid 29446163)
2. Blanck A, Hansson T, Näslund B, and Rane A (1990) Sex differences and endocrine regulation of morphine oxidation in rat liver. Biochem Pharmacol 39:1820-1822.
3. Evans AM, O'Brien J, and Nation RL (1999) Application of a loading wash-out method for investigating the hepatocellular efflux of a hepatically-generated metabolite, morphine-3-glucuronide. J Pharm Pharmacol 51:1289-1297.
4. Fratta W, Casu M, Balestrieri A, Loviselli A, Biggio G, and Gessa GL (1980) Failure of ketamine to interact with opiate receptors. Eur J Pharmacol 61:389-391.
5. Galinski M, Dolveck F, Combes X, Limoges V, Smail N, Pommier V, Templier F, Catineau J, Lapostolle F, and Adnet F (2007) Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emergen Med 25:385-390.
6. Ishii Y, Takami A, Tsuruda K, Kurogi A, Yamada H, and Oguri K (1997) Induction of two UDP-glucuronosyltransferase isoforms sensitive to phenobarbital that are involved in morphine glucuronidation: production of isoform-selective antipeptide antibodies toward UGT1.1r and UGT2B1. Drug Metab Dispos 25:163-167.
7. Iwamoto K, Eaton DL, and Klaassen CD (1978) Uptake of morphine and nalorphine by isolated rat hepatocytes. J Pharmacol Exp Ther 206:181-189.
8. Jensen LL, Handberg G, Helbo-Hansen HS, Skaarup I, Lohse T, Munk T, and Lund N (2008) No morphine sparing effect of ketamine added to morphine for patient-controlled intravenous analgesia after uterine artery embolization. Acta Anaesthesiol Scand 52:479-486.
9. Kannan TR, Saxena A, Bhatnagar S, and Barry A (2002) Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 23:60-65.
10. Lear L, Nation RL, and Stupans I (1991) Influence of morphine concentration on detergent activation of rat liver morphine-UDP- glucuronosyltransferase. Biochem Pharmacol 42:S55-S60.
11. Marietta MP, White PF, Pudwill CR, Way WL, and Trevor AJ (1976) Biodisposition of ketamine in the rat: self-induction of metabolism. J Pharmacol Exp Ther 196:536-544.
12. Milne RW, Jensen RH, Larsen C, Evans AM, and Nation RL (1997) Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig. Pharm Res 14:1014-1018.
13. Milne RW, Nation RL, and Somogyi AA (1996) The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Revs 28:345-472.
14. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
15. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:189-201.
16. Ohno S, Kawana K, and Nakajin S (2008) Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 36:688-694.
17. Projean D, Tu TM, and Ducharme J (2003) Rapid and simple method to determine morphine and its metabolites in rat plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 787:243-253.
18. Rane A, Gawronska-Szklarz B, and Svensson JO (1985) Natural (-)- and unnatural (+)-enantiomers of morphine: comparative metabolism and effect of morphine and phenobarbital treatment. J Pharmacol Exp Ther 234:761-765.
19. Ryder S, Way WL, and Trevor AJ (1978) Comparative pharmacology of the optical isomers of ketamine in mice. Eur J Pharmacol 49:15-23. (Pubitemid 9193621)
20. Sakata RK, Issy AM, Garcia JBS, Martins DC, and Memoria EV (2007) No effect of 10 mg of oral S(+)-ketamine combined with morphine on postoperative analgesia. Acute Pain 9:153-158.
21. Smith DJ, Bouchal RL, deSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, and Crisp T (1987) Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 26:1253-1260.
22. Stain F, Barjavel MJ, Sandouk P, Plotkine M, Scherrmann JM, and Bhargava HN (1995) Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J Pharmacol Exp Ther 274:852-857.
23. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
24. van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, and Borst P (2007) Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72:387-394.
25. White JM and Ryan CF (1996) Pharmacological properties of ketamine. Drug Alcohol Rev 15:145-155.